Statistics
Total Visits
| Views | |
|---|---|
| A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM) | 130 |
Total Visits Per Month
| March 2024 | April 2024 | May 2024 | June 2024 | July 2024 | August 2024 | September 2024 | |
|---|---|---|---|---|---|---|---|
| A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM) | 2 | 0 | 1 | 0 | 2 | 9 | 1 |
Top country views
| Views | |
|---|---|
| Poland | 62 |
| United States | 21 |
| Cyprus | 10 |
| China | 5 |
| Ireland | 3 |
| France | 2 |
| Greece | 2 |
| India | 2 |
| Argentina | 1 |
| Australia | 1 |
Top cities views
| Views | |
|---|---|
| Warsaw | 62 |
| Limassol | 10 |
| San Ramon | 6 |
| Beijing | 4 |
| Dublin | 3 |
| Menlo Park | 3 |
| San Mateo | 3 |
| Athens | 2 |
| Delhi | 2 |
| Des Moines | 2 |